



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Juan S. Izquierdo-Condo
✉ juan1izquierdo11@gmail.com

RECEIVED 10 July 2025
ACCEPTED 28 July 2025
PUBLISHED 20 August 2025

CITATION

Aristizábal-Colorado D, Corredor-Rengifo D, Sierra-Castillo S, López-Corredor C, Vernaza-Trujillo D-A, Weir-Restrepo D, Izquierdo-Condo JS, Ortiz-Prado E, Rico-Fontalvo J, Gómez-Mesa J-E, Abreu-Lomba A and Rivera-Martínez W-A (2025) Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review. *Front. Endocrinol.* 16:1663787. doi: 10.3389/fendo.2025.1663787

COPYRIGHT

© 2025 Aristizábal-Colorado, Corredor-Rengifo, Sierra-Castillo, López-Corredor, Vernaza-Trujillo, Weir-Restrepo, Izquierdo-Condo, Ortiz-Prado, Rico-Fontalvo, Gómez-Mesa, Abreu-Lomba and Rivera-Martínez. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review

David Aristizábal-Colorado^{1,2}, David Corredor-Rengifo^{1,2}, Santiago Sierra-Castillo³, Carolina López-Corredor⁴, David-Alexander Vernaza-Trujillo^{2,5,6}, Danilo Weir-Restrepo⁷, Juan S. Izquierdo-Condo^{8*}, Esteban Ortiz-Prado⁸, Jorge Rico-Fontalvo^{9,10}, Juan-Esteban Gómez-Mesa^{11,12}, Alin Abreu-Lomba¹³ and Wilfredo-Antonio Rivera-Martínez^{2,14}

¹Internal Medicine Department, Universidad Libre, Cali, Colombia, ²Grupo Interinstitucional de Medicina Interna (GIMI1), Universidad Libre, Cali, Colombia, ³Epidemiology Department, Universidad Centros de Estudios en Salud (CES), Medellín, Colombia, ⁴Medicine Program, Universidad Santiago de Cali, Cali, Colombia, ⁵Department of Public Health, Pontificia Universidad Javeriana, Cali, Colombia, ⁶Clinical Research Center, Clínica Imbanaco, Cali, Colombia, ⁷Internal Medicine Department, Universidad Centros de Estudios en Salud (CES), Medellín, Colombia, ⁸One Health Research Group, Universidad de las Américas, Quito, Ecuador, ⁹Department of Nephrology, Faculty of Medicine, Universidad Simón Bolívar, Barranquilla, Colombia, ¹⁰Latin American Society of Nephrology and Arterial Hypertension (SLANH), Ciudad de Panamá, Panamá, ¹¹Cardiology Department, Fundación Valle del Lili, Cali, Colombia, ¹²Department of Health Sciences, Universidad Icesi, Cali, Colombia, ¹³Endocrinology Department, Clínica Imbanaco, Cali, Colombia, ¹⁴Endocrinology Department, Universidad de Antioquia, Medellín, Colombia

KEYWORDS

cardiovascular outcomes, SGLT2 inhibitors, GLP-1 agonists, combination therapy, heart failure, renal outcomes

A Correction on

A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review

By Aristizábal-Colorado D, Corredor-Rengifo D, Sierra-Castillo S, López-Corredor C, Vernaza-Trujillo D-A, Weir-Restrepo D, Izquierdo-Condo JS, Ortiz-Prado E, Rico-Fontalvo J, Gómez-Mesa J-E, Abreu-Lomba A and Rivera-Martínez W-A (2025) *Front. Endocrinol.* 16:1605746. doi: 10.3389/fendo.2025.1605746

The affiliations “Department of Public Health, Pontificia Universidad Javeriana, Cali, Colombia” and “Clinical Research Center, Clínica Imbanaco, Cali, Colombia” were omitted for author David Alexander Vernaza Trujillo.

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.